Amylyx Pharmaceuticals, Inc. [Rocket]

Overview

Amylyx Pharmaceuticals, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
10/13/2023	8-K	Quarterly results
10/04/2023	SC 13D/A	Morningside Venture Investments Ltd reports a 3.4% stake in Amylyx Pharmaceuticals, Inc.
08/24/2023	4	FRATES JAMES M (CFO) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
08/17/2023	4	Morningside Venture Investments Ltd (10% Owner) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
08/17/2023	SC 13D/A	Morningside Venture Investments Ltd reports a 6.9% stake in Amylyx Pharmaceuticals, Inc.
08/17/2023	4	Mazzariello Gina (Chief Legal Officer) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
08/15/2023	144	Form 144 - Report of proposed sale of securities:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20
Revenues	22.2	115.7	0.3	44.0	24.6
Revenue growth	7700.0%	162.7%	-98.8%
Cost of goods sold	3.0	93.5	0.0	43.8	39.7
Gross profit	19.2	22.2	0.3	0.3	-15.1
Gross margin	86.5%	19.2%	100.0%	0.6%	-61.2%
Selling, general and administrative	127.1	127.1	38.9	38.9
Research and development	116.4		44.0
General and administrative					15.1
EBIT	-201.3	-201.3	-82.7	-82.7	-39.0
EBIT margin	-905.7%	-174.0%	-29013.3%	-187.8%	-158.6%
Pre-tax income	-197.6	-197.6	-87.9	-87.9	-42.3
Income taxes	0.8	0.8	0.0	0.0	0.0
Tax rate			0.0%	0.0%	0.0%
Net income	-198.4	-198.4	-87.9	-87.9	-42.3
Net margin	-892.4%	-171.5%	-30853.0%	-199.7%	-171.9%

Diluted EPS	($3.39)	($3.39)	($13.35)	($13.35)	($6.96)
Shares outstanding (diluted)	58.5	58.5	6.6	6.6	6.1

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.